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A commentary on
The Expression of CD123 Can Decrease with Basophil Activation: Implications for the Gating 
Strategy of the Basophil Activation Test
by Santos AF, Bécares N, Stephens A, Turcanu V, Lack G. Clin Transl Allergy (2016) 6:11. doi: 10.1186/
s13601-016-0100-4
Basophil activation test (BAT) is an assay used to diagnose allergy by evaluating the expression 
of surface molecules in circulating and activated basophils with an in vitro flow cytometry (FC) 
approach. Separation of basophils from whole blood is virtually made by an electronic capture in 
FC. This process is called gating and uses a “phenotyping” protocol that targets membrane molecules 
typically or exclusively expressed by circulating basophils. Once “gated,” basophils are examined for 
their expression of molecules, such as CD63, CD203c, or CD193 (CCR3), usually up or downregu-
lated by cellular activation from allergens or non-IgE-mediated stimuli.
A recent article by Santos et al. reported that the CD123/HLA-DR protocol used to gate basophils 
in an FC approach could be fully improved by considering the introduction of CD203c as a gating 
additional molecule, as they reported a degree of correlation between basophil activation (as meas-
ured by the increased expression of CD203c) and decreased expression of CD123 without making 
a direct causal link between both the observations (1). They actually showed that, during cellular 
activation, the expression of membrane CD123, the alpha subunit of the interleukin-3 (IL-3) recep-
tor, is downregulated, leading to a possible loss in the electronic capture of basophils and hence a false 
negative outcome of the activation test (1). Moreover, they suggested the introduction of CD203c 
marker, quite exclusively expressed by basophils, to improve BAT performance (1). In their paper, the 
authors hypothesized also that activated basophils should upregulate membrane expression of the 
class II MHC antigen HLA-DR, but their results confirmed that basophils do not express HLA-DR, 
even during allergic activation (1–4).
The paper by Santos et al. contains interesting issues, which raised comments from this author.
This evidence represents a novelty in the field, as it reports that a phenotyping marker, i.e., CD123, 
should be downregulated during basophil activation. In this regard, the evidence by Santos et al. 
would suggest that gating strategies using CCR3 (CD193), the eotaxin receptor, may be revised, as 
CCR3 is notoriously downregulated during basophil activation and may therefore behave as CD123, 
leading to considerations that would be very interesting to address in next future (1, 3, 5, 6). To the 
best of our knowledge, CD123 has never been considered an activation marker (7). Apparently, 
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its association with a basophil activation marker, exclusively 
expressed by basophils, such as CD203c, should improve the 
ability to capture or gate these cells in FC (1, 7).
The phenotyping protocol widely used to gate basophils 
includes both CD123 and HLA-DR (4). Santos et al. reported that 
while basophil HLA-DR remains unexpressed during any kind 
of activation, either IgE- or non-IgE-mediated, CD123 is down-
regulated on basophil membrane, then it led to a reduction in 
CD123-fluorescent cells captured as dots events in the FC analysis 
and to possible false negatives in the BAT evaluation (1). Previous 
reports of our group showed that CD123 is highly expressed 
(“bright”) on the membrane of basophils undergoing an in vitro 
BAT prior of any activation (3, 4). We also demonstrated, by 
evaluating the mean fluorescence (MFICD123) in the gate, that the 
behavior of CD123, in the protocol CD123bright/HLA-DRneg used 
to gate basophils, was unchanged even following different kinds 
of activation, i.e., CD123 did not significantly change its mem-
brane expression following either an IgE- or a non-IgE-mediated 
basophil activation (3, 4); and furthermore, no evidence of direct 
inhibition of CD123 following basophil activation has been ever 
reported in the literature. My modest opinion is that the observed 
apparent reduction of CD123-FITC may be caused by effects 
related to the gating strategy involving CD203c.
If we gate basophils through a SSC/CD203c approach and 
then evaluate the expression of CD123 and HLA-DR, we might 
be biased about the expression of CD123 by the fact that CD203c 
changes its fluorescence pattern upon activation. Yet, the oppo-
site approach, i.e., gating with a CD123/HLA-DR and then with 
CD203c, was suggested with the purpose to improve basophil 
capture. A gating protocol adopting CD203c as a phenotyping 
marker, due to the upregulation of the latter upon activation, may 
lead to an overestimation of basophil count in the gate.
The authors demonstrated that the introduction of CD203c in 
the CD123/HLA-DR phenotyping protocol leads to a reduction 
in the loss of basophils in the gate and ameliorated the ability to 
catch basophils expressing CD63, thus preventing possible bias 
in the diagnostic value of BAT (1). The authors showed in Figure 
5b of their manuscript, an evidence that should recall perfectly a 
circumstance published by ours elsewhere [Figure 4, page 8/14 of 
Ref. (4)], showing the expression of CD63 and CD203c following 
an fMLP-induced activation, i.e., dot plot of Ref. (1) is quite per-
fectly akin dot plot of Ref. (4). The authors reported this evidence 
as particularly meaningful of their conclusions. They assessed 
that following fMLP activation, the reduction in the number of 
gated cells with a CD123/HLA-DR protocol was highly signifi-
cant (p < 0.004) compared with anti-IgE (p < 0.99), which was 
exactly the opposite opinion of others, reporting a CD123 quite 
unchanged upon fMLP activation (1, 4). Interestingly, the image 
reported in Ref. (4) is perfectly comparable to the one reported 
by the authors in Figure 5b of their paper and, as Chirumbolo 
et  al. sustained the evidence that CD123 was expressed in a 
bright form and unchanged during activation (3, 4), the occur-
rence of the same evidence with opposite opinions on CD123 is 
particularly intriguing and deserves further research considera-
tions. Moreover, the authors succeeded in counting more than 
5,000 basophils in the gate using the same volume of sample. 
Usually, the theoretical number of basophils in 100 μl heparin- 
anticoagulated whole blood ranges from 103 to 104, but this num-
ber may be much lower due to yield concerns. During activation, 
the authors reported higher values of basophils in the gate when 
captured with only CD203c, i.e., SSC/CD203c, showing a slight 
overestimation due to changes in CD203c membrane expression, 
although it is possible to argue that the number of basophils in the 
gate may be underestimated in non-stimulated conditions since 
low expressing CD203c basophils would be missed.
Aside for the need to expand the debate about improvements 
in BAT strategy, this analytical test remains a formidable tool to 
diagnose allergy, and the ability to test activation depends also on 
the optimization of the gating strategy (8, 9).
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